Jim Cramer Says “No One Disputes the Science and Commercial Smarts of Abbott”

Abbott Laboratories (NYSE:ABT) was among the stocks Jim Cramer talked about as he discussed the recent rally in several AI-related stocks. Cramer mentioned the company during the episode and stated:

Now, let’s talk about some legendary growth companies and what’s happened to their stocks. Consider three really high-quality MedTech companies: Abbott Labs, Boston Scientific, and Medtronic. The price-to-earnings multiple compression of these stellar stocks is extraordinary. No one disputes the science and commercial smarts of Abbott, but it trades at just 16 times earnings now. The stock was at $133 this week last year; it’s now at $87 and change. Boston Scientific was long held as the premium heart device company. The stock’s been cut in half, in half, and now sells for 14 times earnings.

Medtronic reports this week. It’s down 23% for the year and yields almost 4%, trades at just 13 times earnings. And all these stocks, they just seem to fall in time. We’ve long bid up the prices of our best precision instrument companies…. These are companies that are loaded with technology and intellectual property, but their stocks are now disliked. And given their actual growth rates, perhaps they should be, because they just can’t compete with the data center plays.

Stock market data. Photo by Jakub Zerdzicki on Pexels

Abbott Laboratories develops and sells healthcare products, including generic medicines, diagnostic systems, nutrition brands, cardiovascular and diabetes care devices, and neuromodulation technologies.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Follow Insider Monkey on Google News.